LHRH agonist

Org: European Institute of Oncology, Milan, Italy, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center, Boston, MA, Peter MacCallum Cancer Centre, Melbourne, Australia, European Institute of Oncology IRCCS, and University of Milan, Milano, Italy, Breast Unit, Helios University Clinic, University Witten-Herdecke, Wuppertal, Germany,

Clinical trial

Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2017-07-10

Clinical trial

A Randomized, Phase II Study for Premenopausal Metastatic or Locally Advanced Breast Cancer Patients: Capivasertib, Goserelin, Fulvestrant With/Without Durvalumab, Versus Goserelin, Fulvestrant, and Durvalumab, Versus Goserelin/ Fulvestrant.

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in Combination With Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor

Status: , Estimated PCD: 2027-05-31

Clinical trial

Cross-Over Trial to Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer

Status: Recruiting, Estimated PCD: 2025-05-01

Clinical trial

A Phase 2 Trial of Radium Ra 223 Dichloride in Combination With Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients With Oligometastatic Castration Sensitive Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2025-04-09

Clinical trial

A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune)

Status: Recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Phase II Study of Ipilimumab PLUS Androgen Depravation Therapy in Castrate Sensitive Prostate Carcinoma

Status: Terminated, Estimated PCD: 2017-04-07

Clinical trial

A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2021-04-13

Clinical trial

Gonadotropin Releasing Hormone Agonist for Luteal Phase Support in Gonadotropin Releasing Hormone Antagonist Protocol Cycles

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

A Phase 2 Study of Darolutamide in Combination With Leuprolide Acetate in Hormone-Therapy Naive Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer

Status: Recruiting, Estimated PCD: 2027-04-11

Clinical trial

Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients

Status: , Estimated PCD: 2020-12-01

Clinical trial

A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2014-05-01

Clinical trial

CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2024-05-15

Clinical trial

Utility of Exosomal microRNAs to Predict Response to Androgen Deprivation Therapy in Prostate Cancer Patients

Status: Active (not recruiting), Estimated PCD: 2021-05-11

Clinical trial

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma: a Single-arm Phase 2 Trial

Status: Recruiting, Estimated PCD: 2029-03-30

Clinical trial

Phase II Study of Darolutamide (ODM-201) in Patients With Androgen Receptor-positive Salivary Gland Carcinoma (Discovary Study)

Status: Active (not recruiting), Estimated PCD: 2024-08-01

Clinical trial

Gonadotropin Releasing Hormone Agonist for Luteal Phase Support in Long Gonadotropin Releasing Hormone Agonist Protocol Cycles

Status: Recruiting, Estimated PCD: 2024-12-31

Clinical trial

Phase II, Multicenter, Single Arm Trial to Assess the Feasibility of First Line Ribociclib in Combination With a Non Steroidal Aromatase Inhibitor in Elderly Patients With Hormone Receptor Positive/HER2 Negative Advanced Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2024-12-27

Clinical trial

Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Status: Recruiting, Estimated PCD: 2025-07-31

Clinical trial

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2020-05-05

Clinical trial

Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)

Status: Active (not recruiting), Estimated PCD: 2024-12-31

Clinical trial

Asian, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tamoxifen With or Without Palbociclib ± Goserelin in Women With Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Status: Active (not recruiting), Estimated PCD: 2025-09-01

Clinical trial

Androgen Deprivation and Localized Radiotherapy to Metastases in Patients With Oligometastatic Hormone - Sensitive Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2011-03-16

Clinical trial

Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC-RP Trial): A Randomized, Open-label, Multi-centre Phase-2 Study Evaluating the Pathological Complete Response (pCR) Rate Following Neoadjuvant Therapy in Participants With High-risk Prostate Carcinoma for Whom Radical Prostatectomy is Indicated

Status: Completed, Estimated PCD: 2021-05-27

Clinical trial

A Phase I/II Study of High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2021-12-14

Clinical trial

Phase II, Open-label, Single-center Study Evaluating Safety and Activity of Androgen Deprivation Therapy Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Status: Active (not recruiting), Estimated PCD: 2024-03-01

Clinical trial

A Neoadjuvant Phase IIa Study of Ipilimumab {Formerly Known as MDX-010 (BMS-734016)} Plus Hormone Ablation in Men With Prostate Cancer Followed by Radical Prostatectomy.

Status: Completed, Estimated PCD: 2015-10-01

Clinical trial

The Effects of GnRH-a on Angiogenesis of Endometriosis

Status: Completed, Estimated PCD: 2023-01-01

Clinical trial

Comparison Between Effects of Dydrogesterone, Cetrorelix Acetate and Triptorelin on Intra Cytoplasmic Sperm Injection Outcomes

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical Prostatectomy

Status: , Estimated PCD: 2018-07-12

Clinical trial

Assessing the Efficacy and Safety of Optimal Neoadjuvant to Adjuvant Anti-HER2- Based Therapy in Nigerian Women With HER2+ Breast Cancer

Status: Not yet recruiting, Estimated PCD: 2034-07-01

Clinical trial

Bipolar Androgen Therapy in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Recruiting, Estimated PCD: 2026-04-01

Clinical trial

ARN-509+Abiraterone Acetate+Leuprolide With Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study

Status: Active (not recruiting), Estimated PCD: 2026-05-01

Clinical trial

Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2019-12-01

Clinical trial

RecoverPC: A Phase 2 Study of RElugolix Versus GnRH Agonist Quality of Life (QOL) and Testosterone reCOVERy in Men With Prostate Cancer

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

A Multi-Center Trial of Androgen Suppression With Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS): A Phase I/2 Trial in High Risk and Node Positive Prostate Cancer

Status: Recruiting, Estimated PCD: 2026-11-01

Clinical trial

Assisted Reproductive Technology (ART) and Pregnancy Outcomes in Women With Adenomyosis (Internal Endometriosis) According to Stimulation Protocol in Relation to Immunological and Endometrial Features: a Prospective, Randomized Study

Status: Recruiting, Estimated PCD: 2025-03-01

Clinical trial

A Single-Arm, Open-Label, Phase II Study of Systemic and Tumor Directed Therapy for Recurrent Oligometastatic M1 Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2025-01-01

Clinical trial

A Phase 2 Randomized Pre-operative,Window of Opportunity Trial Investigating the Effect of Elacestrant With/Without Triptorelin in Premenopausal Patients With HR+/HER2- Breast Cancer - SOLTI-2104-PremiÈRe Trial.

Status: Recruiting, Estimated PCD: 2024-10-01

Clinical trial

A Phase I Study Of Combination Neoadjuvant Hormone Therapy And Weekly OGX-011 (Clusterin Antisense Oligonucleotide) Prior To Radical Prostatectomy In Patients With Localized Prostate Cancer

Status: Completed, Estimated PCD: 2004-09-23

Clinical trial

A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)

Status: , Estimated PCD: 2029-09-07

Clinical trial

A Multicenter，Prospective Clinical Trial for Reducing Remaining Submucous Fibroids Volume and Preventing Recurrence by Treating With GnRH Analogues or Mifepristone After Transcervical Resection of Type I-II Myoma

Status: Not yet recruiting, Estimated PCD: 2024-12-30

Clinical trial

Phase III Randomised Trial to Evaluate the Benefit of Adjuvant Hormonal Treatment With Leuprorelin Acetate (Eligard® 45 mg) for 24 Months After Radical Prostatectomy in Patients With High Risk of Recurrence.

Status: Active (not recruiting), Estimated PCD: 2027-09-01

Clinical trial

A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

Status: Active (not recruiting), Estimated PCD: 2028-05-31

Clinical trial

"A Randomized Multicenter Phase II Trial to Evaluate the Effectiveness of Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients"

Status: Completed, Estimated PCD: 2010-09-01

Clinical trial

Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast

Status: Recruiting, Estimated PCD: 2024-04-01

Clinical trial

Phase II Study of Palifermin With Leuprolide Acetate or Degarelix For the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Status: Active (not recruiting), Estimated PCD: 2024-12-01

Clinical trial

An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2019-04-10

Clinical trial

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

Status: Completed, Estimated PCD: 2024-03-31

Clinical trial

The Impact of Adjuvant Androgen Deprivation Following Radical Prostatectomy on Prostate Cancer Recurrence

Status: Recruiting, Estimated PCD: 2023-11-01

Clinical trial

Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data

Status: Completed, Estimated PCD: 2021-08-01

Clinical trial

Assessing REsponse to Neoadjuvant Taxotere and Trastuzumab in Nigerian Women With HER2-positive Breast Cancer (ARETTA)

Status: Recruiting, Estimated PCD: 2023-09-10

Clinical trial

The Treatment of Menstrually-Related Mood Disorders With the Gonadotropin Releasing Hormone (GnRH) Agonist, Depot Leuprolide Acetate (Lupron)

Status: Completed, Estimated PCD: 2020-02-06

Clinical trial

Presurgical Treatment With Ribociclib and Letrozole in Patients With Locally Advanced Breast Cancer: the NEOLETRIB Study.

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

Mechanism and Predictors of Cardiotoxicity After Prostate Cancer Treatment: A Parallel Cohort and Randomized Trial Comparing Radiation Alone, Radiation Plus Leuprolide, and Radiation Plus Relugolix

Status: Active (not recruiting), Estimated PCD: 2025-01-30

Clinical trial

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

Status: Recruiting, Estimated PCD: 2023-08-15

Clinical trial

A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2018-10-02

Clinical trial

A Randomized Phase III Study Comparing Cyclophosphamide + Methotrexate + Fluorouracil vs. Goserelin + Tamoxifen in Premenopausal, Hormone Receptor-positive, Lymph Node-positive or -Negative Patients

Status: Completed, Estimated PCD: 2004-06-01

Abstract

LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.

Org: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Harbin Medical University Cancer Hospital, Harbin, China, Genor Biopharma Co., Ltd, Beijing, China, Genor Biopharma Co., Ltd., Beijing, China,

Abstract

Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial.

Org: David Geffen School of Medicine at University of California Los Angeles, Moscow City Oncology Hospital No.62, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, National Taiwan University Hospital,

Abstract

A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE).

Org: Mayo Clinic, Rochester, MN, Phoenix, AZ, Jacksonville, FL, Clear Lake Oncology,

Abstract

Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy.

Org: National Cancer Center Hospital East, Kashiwa, Japan, Kobe University Hospital, National Hospital Organization Kyushu Medical Center, Osaka International Cancer Institute, Osaka, Japan, Tohoku University Hospital,

Abstract

Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.

Org: American University of Beirut Medical Center, National Cancer Centre of Singapore, Acıbadem Research Institute of Senology, Medical Oncology, Seoul National University Hospital, Independent Patient Advocate,

Abstract

Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial.

Org: National Cancer Center Hospital East, Chiba, Japan, National Cancer Center Hospital, Tokyo, Japan, Kanagawa Cancer Center, Kanagawa, Japan, Chiba Cancer Center, Chiba, Japan, Koo Foundation Sun Yat-sen Cancer Center, Taipei, Taiwan,

Abstract

PSMA PET findings in an “EMBARK-like” cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: A single center post-hoc retrospective analysis.

Org: UCLA-Caltech Medical Scientist Training Program, UCLA Ahmanson Translational Theranostics Division, UCLA Department of Radiation Oncology, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, University of California Irvine,

Abstract

Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial.

Org: Dana-Farber Cancer Institute, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, Beth Israel Deaconess Medical Center, Janssen Research & Development,

Abstract

Propensity score matched analysis of major adverse cardiac events in patients with localized prostate cancer receiving short term vs long term ADT.

Org: Atropos Health, Beth Israel Deaconess Medical Center,

Abstract

Neoadjuvant stereotactic body radiotherapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer.

Org: Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China,

Abstract

Gemcitabine, cisplatin, nab-paclitaxel: The effectiveness of this regimen for gall bladder cancer.

Org: Tata Memorial Hospital (HBNI), Tata Memorial Centre, Tata Memorial Center (HBNI),

Abstract

Association of albumin and neutrophil-to-lymphocyte ratio with hormone-mediated depression in prostate cancer.

Org: Miami Cancer Institute - Baptist Health South Florida,

Abstract

The PRIME-CUT study: A single-arm phase 2 study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer.

Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center, Spectrum Medical Group, Columbia University Irving Medical Center, New York, NY, USA, Columbia University Medical Center,

Abstract

Pembrolizumab immunotherapy in advanced and recurrent/metastatic salivary gland carcinoma (R/M SGC): A systematic review and meta-analysis.

Org: Federal University of Pelotas, Pelotas, Brazil, Brazil, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil,

Abstract

Cardiovascular comorbidities and cardiovascular events in patients with metastatic prostate cancer.

Org: Laboratoire Toxicomed, University of Tlemcen, Tidjani Damerdji Teaching Hospital, CHU Tlemcen,

Product

Gotistobart

Product

dalpiciclib, exemestane, and goserelin

Product

Adjuvant endocrine therapy